Interaction of Neisseria meningitidis with human dendritic cells

Infection and Immunity

Volumn 69, Issue 11, 2001, Pages 6912-6922

  Kolb Maurer A ^a   Unkmeir, A ^a   Kammerer U ^a   Hubner C ^a   Leimbach, T ^a   Stade, A ^a   Kampgen E ^a   Frosch, M ^a   Dietrich, G ^a  

^a Berna Biotech AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 1; INTERLEUKIN 6; INTERLEUKIN 8; OLIGOSACCHARIDE; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; BACTERICIDAL ACTIVITY; BACTERIUM ADHERENCE; BACTERIUM CULTURE; CELL ACTIVATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; DENDRITIC CELL; DISEASE SEVERITY; EPIDEMIC MENINGITIS; HUMAN; HUMAN CELL; NEISSERIA MENINGITIDIS; PHAGOCYTE; PHAGOSOME; PRIORITY JOURNAL; SEPTICEMIA;

ADULT; BACTERIAL ADHESION; CELL DIFFERENTIATION; CELLS, CULTURED; CYTOKINES; DENDRITIC CELLS; HUMANS; NEISSERIA MENINGITIDIS; PHAGOCYTOSIS;

EID: 0034783473     PISSN: 00199567     EISSN: None     Source Type: Journal    
DOI: 10.1128/IAI.69.11.6912-6922.2001     Document Type: Article

References (61)

1. Neisseria meningitidis: Vaccines and vaccine candidates
2. Prevention of meningococcal disease by group C polysaccharide vaccine
3. Dendritic cells and the control of immunity
4. Compartmentalization of lipopolysaccharide production correlates with clinical presentation in meningococcal disease
5. Tumor necrosis factor, its receptors and the connection with interleukin 1 and interleukin 6
6. Neisseria meningitidis: Clinical aspects
7. A quantitative analysis of APC function: Activated B cells stimulate naive CD4 T cells but are inferior to dendritic cells in providing costimulation
8. Is group C meningococcal disease increasing in Europe? A report of surveillance of meningococcal infection in Europe 1993-1996
9. Randomized, placebo-controlled trial of HA-1A, a human monoclonal antibody to endotoxin, in children with meningococcal septic shock
10. Regulation of dendritic cell numbers and maturation by lipopolysaccharide in vivo
11. Release of endotoxin in the form of cell wall blebs during in vitro growth of Neisseria meningitidis
12. Dendritic cell activation and cytokine production induced by group B Neisseria meningitidis: Interleukin 12 production depends on lipopolysaccharide expression in intact bacteria
13. Nonopsonic phagocytosis of group C Neisseria meningitidis by human neutrophils
14. Brain dendritic cells and macrophages/microglia in central nervous system inflammation
15. Preliminary evaluation of recombinant amino-terminal fragment of human bactericidal/ permeability-increasing protein in children with severe meningococcal sepsis
16. Prospects for the prevention of bacterial meningitis with polysaccharide vaccines
17. Early events in dendritic cell maturation induced by LPS
18. Contribution of genes from the capsule gene complex (cps) to lipooligosaccharide biosynthesis and serum resistance in Neisseria meningitidis
19. Age-related differences in outcome and severity of DIC in children with septic shock and purpura
20. Serotypes of Neisseria meningitidis isolated from patients in Norway during the first six months of 1978
21. Dendritic cell progenitors phagocytose particulates, including bacillus Calmette-Guerin organisms, and sensitize mice to mycobacterial antigens in vivo
22. Membrane-associated proteins of a lipopolysaccharide-deficient mutant of Neisseria meningitidis activate the inflammatory response through Toll-like receptor 2
23. Meningococcal vaccines
24. Listeria monocytogenes-infected human dendritic cells: Invasion and host cell response
25. Bacterial meningitis: Mechanisms of disease and therapy
26. Gram-negative bacteremia. III. Reassessment of etiology, epidemiology and ecology in 612 patients
27. Gene expression and production of tumor necrosis factor alpha, interleukin-1β10 (IL-β), IL-8, macrophage inflammatory protein lα (MIP-lα), MIP-10, and gamma interferon-inducible protein 10 by human neutrophils stimulated with group B meningococcal outer membrane vesicles
28. Pathogenesis of bacterial meningitis
29. Recombinant bactericidal/permeability-increasing protein (rBPI21) as adjunctive treatment for children with severe meningococcal sepsis: A randomised trial
30. Immunoglobulin A1 protease, an exoenzyme of pathogenic neisseriae, is a potent inducer of proinflammatory cytokines
31. Distribution and phenotype of dendritic cells and resident tissue macrophages in the dura mater, leptomeninges, and choroid plexus of the rat brain as demonstrated in wholemount preparations
32. Interactions of Neisseria meningitidis with human monocytes
33. Carcinoembryonic antigen family receptor specificity of Neisseria meningitidis Opa variants influences adherence to and invasion of proinflammatory cytokine-activated endothelial cells
34. Tumor necrosis factor in mediating experimental Haemophilus influenzae type B meningitis
35. Tumour necrosis factor α antibody protects against lethal meningococcaemia
36. Defective regional immunity in the respiratory tract of neonates is attributable to hyporesponsiveness of local dendritic cells to activation signals
37. Cerebrospinal fluid concentrations of interleukin-1β, tumour necrosis factor-α, and interferon gamma in bacterial meningitis
38. Cerebrospinal fluid cytokine levels and dexamethasone therapy in bacterial meningitis
39. Meningococcal disease: Still with us
40. A lipopolysaccharide-deficient mutant of Neisseria meningitidis elicits attenuated cytokine release by human macrophages and signals via Toll-like receptor (TLR) 2 but not via TLR4/MD2
41. Modulating the immune response with dendritic cells and their growth factors
42. Tumor necrosis factor α/cachectin and interleukin 1 beta initiate meningeal inflammation
43. The (α2→8)-linked polysialic acid capsule of group B Neisseria meningitidis modifies multiple steps during interaction with human macrophages
44. Analysis of adjuvant function by direct visualization of antigen presentation in vivo: Endotoxin promotes accumulation of antigen-bearing dendritic cells in the T cell areas of lymphoid tissue
45. The role of dendritic cells in the induction and regulation of immunity to microbial infection
46. Proliferating dendritic cell progenitors in human blood
47. Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/ macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor α
48. Dendritic cells use macropinocytosis and the mannose receptor to concentrate macromolecules in the major histocompatibility complex class II compartment: Downregulation by cytokines and bacterial products
49. Monocytederived IL-10-secreting dendritic cells in choroid plexus epithelium
50. C-X-C and C-C chemokines are expressed in the cerebrospinal fluid in bacterial meningitis and mediate chemotactic activity on peripheral blood-derived polymorphonuclear and mononuclear cells in vitro
51. Reduction of inflammation, tissue damage, and mortality in bacterial meningitis in rabbits treated with monoclonal antibodies against adhesion-promoting receptors of leukocytes
52. Gram-negative bacteria induce proinflammatory cytokine production by monocytes in the absence of lipopolysaccharide
53. Correlation between proinflammatory cytokines and antiinflammatory mediators and the severity of disease in meningococcal infections
54. Immune fate decided by dendritic cell provocateurs
55. The role of pili in the interactions of pathogenic Neisseria with cultured human endothelial cells
56. Regulation of toll-like receptors in human monocytes and dendritic cells
57. Mechanisms of neisserial serum resistance
58. Association between tumour necrosis factor in serum and fatal outcome in patients with meningococcal disease
59. Local production of tumor necrosis factor a, interleukin 1, and interleukin 6 in meningococcal meningitis: Relation to the inflammatory response
60. The complex pattern of cytokines in serum from patients with meningococcal septic shock: Association between interleukin 6, interleukin 1, and fatal outcome
61. Treatment of gram-negative bacteremia and septic shock with HA-1A human monoclonal antibody against endotoxin. A randomized, double-blind, placebo-controlled trial